UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State
or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS
Employer Identification No.) |
(Address of principal executive offices) | (Zip Code) |
Registrant’s
telephone number, including area code:
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Exchange Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
The Stock Market LLC | ||||
Preferred Stock Purchase Rights |
The Nasdaq Stock Market LLC | |||
Warrants, each warrant exercisable for one share of common stock, each at an exercise price of $5.00 per share | BFRIW | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (the “Exchange Act”) (§240.12b-2 of this chapter).
Emerging
growth company
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02 Results of Operations and Financial Condition.
On January 9, 2023, Biofrontera, Inc. (the “Company”) issued a press release announcing its preliminary unaudited revenues for the fourth quarter and year ended December 31, 2022. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K (the “Form 8-K”) and is incorporated herein by reference.
The information contained in this Item 2.02 in this Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall such information be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
The financial information set forth in this Form 8-K reflects the Company’s current preliminary revenue estimates, is subject to the completion of its review process, and is subject to change. The Company’s fourth quarter and full year ended December 31, 2022 results could differ materially from the preliminary estimates provided in this Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which reflect management’s analysis only as of the date of this Form 8-K. The Company undertakes no obligation to publicly release the results of any revision or update of the forward-looking statements, except as required by law.
Item 9.01 Financial Statements and Exhibits.
99.1 | Press release dated January 9, 2023 |
104 | Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
January 9, 2023 | Biofrontera Inc. |
(Date) | (Registrant) |
/s/ Fred Leffler | |
Fred Leffler | |
Chief Financial Officer |
Exhibit 99.1
Biofrontera Inc. Announces Preliminary Revenues
for the Fourth Quarter and Full Year 2022
WOBURN, Mass. (January 9, 2023) – Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced preliminary, unaudited revenues for the three and 12 months ended December 31, 2022.
Revenues for the fourth quarter of 2022 are anticipated to be in the range of approximately $10.2 million to $10.4 million, an increase of approximately 12% compared with the fourth quarter of 2021. These projections result in 2022 revenue of approximately $28.7 million to $28.9 million, a record high and up approximately 20% compared with 2021.
“The Biofrontera team continues to implement our strategy to expand the use of Ameluz®-PDT for the treatment of patients with actinic keratosis,” said Erica Monaco, Chief Executive Officer of Biofrontera, Inc. “Our record 2022 revenue is an important step forward while we continue to build the commercial infrastructure necessary to effectively address and grow in our attractive target market. We are looking forward to building momentum as we move through 2023.”
The preliminary, unaudited revenues described in this press release are estimates only and are based on currently available information. Final results may vary from the preliminary revenue estimates. Biofrontera expects to report financial results for the fourth quarter and full year 2022 in March 2023. Details concerning that announcement and conference call will be provided in the coming weeks.
Biofrontera Inc. management will be in San Francisco from January 9-11, 2023 during the 41st Annual J.P. Morgan Healthcare Conference holding meetings with investors, analysts and prospective business partners. Please email tpatel@lhai.com to request a meeting.
About Biofrontera Inc.
Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company’s licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. For more information, visit www.biofrontera-us.com.
1 |
Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. These statements include, but are not limited to, the Company’s preliminary revenues for the three and twelve months ended December 31, 2022, statements relating to the Company’s business and marketing strategy, the development of the Company’s sales and marketing teams and the potential to expand the label of Ameluz®. We have based these forward-looking statements on our current expectations and projections about future events, nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements we make. These risks and uncertainties, many of which are beyond our control, including, but not limited to, the impact of extraordinary external events, such as the current COVID-19 pandemic; any changes in the Company’s relationship with its licensors; the ability of the Company’s licensors to fulfill their obligations to the Company in a timely manner; the Company’s ability to achieve and sustain profitability; whether the current global disruptions in supply chains will impact the Company’s ability to obtain and distribute its licensed products; changes in the practices of healthcare providers, including any changes to the coverage, reimbursement and pricing for procedures using the Company’s licensed products; the uncertainties inherent in the initiation and conduct of clinical trials; availability and timing of data from clinical trials; whether results of earlier clinical trials or trials of Ameluz® in combination with BF-RhodoLED® in different disease indications or product applications will be indicative of the results of ongoing or future trials; uncertainties associated with regulatory review of clinical trials and applications for marketing approvals; whether the market opportunity for Ameluz® in combination with BF-RhodoLED® is consistent with the Company’s expectations; the Company’s ability to complete the transition to a public company; the Company’s ability to retain and hire key personnel; the sufficiency of cash resources and need for additional financing and other factors that may be disclosed in the Company’s filings with the SEC, which can be obtained on the SEC website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.
Contacts:
Biofrontera Investor Relations
ir@bfinc.com
LHA Investor Relations
Tirth T. Patel
212-201-6614
tpatel@lhai.com
2 |
Cover |
Jan. 09, 2023 |
---|---|
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Jan. 09, 2023 |
Entity File Number | 001-40943 |
Entity Registrant Name | Biofrontera Inc. |
Entity Central Index Key | 0001858685 |
Entity Tax Identification Number | 47-3765675 |
Entity Incorporation, State or Country Code | DE |
Entity Address, Address Line One | 120 Presidential Way |
Entity Address, Address Line Two | Suite 330 |
Entity Address, City or Town | Woburn |
Entity Address, State or Province | MA |
Entity Address, Postal Zip Code | 01801 |
City Area Code | (781) |
Local Phone Number | 245-1325 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Entity Emerging Growth Company | true |
Elected Not To Use the Extended Transition Period | false |
Entity Information, Former Legal or Registered Name | Not Applicable |
Common stock, par value $0.001 per share | |
Title of 12(b) Security | Common stock, par value $0.001 per share |
Trading Symbol | BFRI |
Security Exchange Name | NASDAQ |
/-(%O$&A*;+4T9*YH;7V]%RT.F-);
M7 SW?S\.;RX_5S=ZVK#WTF2_?%]
M>.&TV1S.L:+7AT=4!WO:(3;EY $[(_^6W1$;;\CK+S_C1]XW(;TL2P>I%U]3
M>SKZ^?BY66]J7T?E&AUHS\S/,PA[]R.^U!'"=Q9=9-%BN\^B=TI7YI1P$&,L
MW8*R%L:MV[?Z:4:DC4;_61AW?H-FL3Z5*, 'QF%%^$@D=/4K7?N(5TRAR'&S5Z].%.8/BBV(
M6H]9W#R>5&VAU'%S5K]2%.Q/9#5*C-MLRHI%1Y\TLY1
M8>=K\*(]W*'W4,^)>?ZN6&H\L$N^,[&Y'^1X@.
'!<,15%7-C%"IT&V[K(%L-SU2^<2P1
M^%O:#0=V'>NV3&3VI[#@;@3G;7WZ*.-',%51&Z NR3 T<55W['>HSO63#1S
M]R";"]'G$&LS\G@]@;1\BYH6N;"B:3V XEU[P7D_JVK021P:&Q^D"RV"G[),
M0O7W8L$J>)@"V>1CKPQ3T^661$'E^"WFAI1OP-UQ$V=+T70:>.);'3! TYMW
M'@JB=UA-X=>. ZFQ3FD5P-$.0&NE!552Z[3;6:KO]O0X]"MB7M(BGF[\G40S
M M$I@F+ A+[/8$0\F*GY /D4)PYQ82CF-8F+B11MH ]$S)A\.ZD)I+FD-DA8
M]%DD;&>.01Q3H81L[DI, #NE9[2&'X(G"[=W 3&<;K1(